Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062109 | 0.96 | CHRNA7 (0.61) | CHRNA7ALDH1A1POLBHTR3ACHRM2 | |
| SCHEMBL7063264 | 0.85 | CHRNA7 (0.59) | CHRNA7ALDH1A1POLBHTR3A | |
| SCHEMBL7059190 | 0.85 | CHRNA7 (0.59) | CHRNA7ALDH1A1POLBHTR3A | |
| SCHEMBL7218004 | 0.85 | ALDH1A1 (0.51) | CHRNA7ALDH1A1POLBHTR3A | |
| SCHEMBL6490697 | 0.83 | CHRNA7 (0.43) | CHRNA7ALDH1A1POLBHTR3A | |
| SCHEMBL7062721 | 0.83 | ALDH1A1 (0.60) | CHRNA7ALDH1A1POLBHTR3ACHRM2 | |
| SCHEMBL6494673 | 0.83 | NPC1 (0.64) | CHRNA7ALDH1A1POLB | |
| SCHEMBL6492511 | 0.83 | ALDH1A1 (0.52) | CHRNA7ALDH1A1POLBHTR3A | |
| SCHEMBL6492457 | 0.83 | CHRNA7 (0.48) | CHRNA7ALDH1A1POLB | |
| SCHEMBL6492453 | 0.83 | CHRNA7 (0.48) | CHRNA7ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | CHRNA7 1097/4885ALDH1A1 625/4885POLB 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.